Correlation Between Morgan Stanley and Plus Therapeutics

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Plus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Plus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and Plus Therapeutics, you can compare the effects of market volatilities on Morgan Stanley and Plus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Plus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Plus Therapeutics.

Diversification Opportunities for Morgan Stanley and Plus Therapeutics

0.32

Correlation Coefficient

Morgan Stanley  Plus Therapeutics

Weak diversification

The 3 months correlation between Morgan and Plus is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Plus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plus Therapeutics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Plus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plus Therapeutics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Plus Therapeutics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Plus Therapeutics

Given the investment horizon of 90 days Morgan Stanley Direct is expected to under-perform the Plus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Morgan Stanley Direct is 50.62 times less risky than Plus Therapeutics. The stock trades about -0.01 of its potential returns per unit of risk. The Plus Therapeutics is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  116.00  in Plus Therapeutics on December 27, 2024 and sell it today you would earn a total of  31.00  from holding Plus Therapeutics or generate 26.72% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Morgan Stanley Direct  vs.  Plus Therapeutics

Morgan Stanley Direct

Risk-Adjusted Performance

Very Weak

Over the last 90 days Morgan Stanley Direct has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Morgan Stanley is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors.

Plus Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Plus Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Plus Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Morgan Stanley and Plus Therapeutics

The main advantage of trading using opposite Morgan Stanley and Plus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Plus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plus Therapeutics will offset losses from the drop in Plus Therapeutics' long position.

The idea behind Morgan Stanley Direct and Plus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.